Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free GH Stock Alerts

Guardant Health (GH) Financials

Guardant Health logo
$127.03 -3.14 (-2.41%)
Closing price 04:00 PM Eastern
Extended Trading
$127.11 +0.08 (+0.06%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Guardant Health

Annual Income Statements for Guardant Health

This table shows Guardant Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -46 -89 -85 -76 -254 -406 -655 -479 -436 -416
Consolidated Net Income / (Loss)		 -46 -83 -84 -68 -246 -385 -655 -479 -436 -416
Net Income / (Loss) Continuing Operations		 -46 -83 -84 -68 -246 -385 -655 -479 -436 -416
Total Pre-Tax Income 		-46 -83 -84 -70 -246 -384 -653 -479 -435 -418
Total Operating Income		 -44 -77 -93 -82 -255 -411 -544 -565 -444 -437
Total Gross Profit		 25 47 87 206 269 361 441 337 449 633
Total Revenue		 25 50 91 214 287 374 450 564 739 982
Operating Revenue		 25 50 91 214 287 374 450 564 739 982
Total Cost of Revenue		 0.06 2.74 3.36 8.47 18 13 8.13 227 290 349
Operating Cost of Revenue		 0.06 2.74 3.36 8.47 18 13 8.13 227 290 349
Total Operating Expenses		 69 124 180 288 524 772 986 902 893 1,070
Selling, General & Admin Expense		 9.92 37 36 61 193 207 164 239 180 211
Marketing Expense		 26 32 53 78 107 192 300 295 365 495
Research & Development Expense		 11 26 51 86 150 263 374 367 348 364
Total Other Income / (Expense), net		 -2.29 -6.60 8.72 13 9.05 27 -106 86 8.51 20
Interest Expense		 3.02 7.78 1.25 1.18 4.77 2.58 100 2.58 2.58 3.90
Interest & Investment Income		 0.73 2.23 5.27 14 10 3.93 6.07 35 54 34
Other Income / (Expense), net		 -0.00 -1.06 4.70 0.09 3.64 25 -13 53 -43 -10
Income Tax Expense		 0.01 0.01 0.04 -1.87 0.38 0.30 1.14 0.69 1.28 -1.26
Basic Earnings per Share		 ($3.53) ($7.07) ($2.80) ($0.84) ($2.60) ($4.00) ($6.41) ($4.28) ($3.56) ($3.32)
Weighted Average Basic Shares Outstanding		 13.05M 12.58M 30.40M 90.60M 97.50M 101.31M 102.18M 111.99M 122.75M 125.37M
Diluted Earnings per Share		 ($3.53) ($7.07) ($2.80) ($0.84) ($2.60) ($4.00) ($6.41) ($4.28) ($3.56) ($3.32)
Weighted Average Diluted Shares Outstanding		 13.05M 12.58M 30.40M 90.60M 97.50M 101.31M 102.18M 111.99M 122.75M 125.37M
Weighted Average Basic & Diluted Shares Outstanding		 13.05M 12.58M 30.40M 90.60M 97.50M 101.87M 102.66M 121.71M 123.42M 131.17M

Quarterly Income Statements for Guardant Health

This table shows Guardant Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -86 -187 -115 -103 -108 -111 -95 -100 -93 -128 -112
Consolidated Net Income / (Loss)		 -86 -187 -115 -103 -108 -111 -95 -100 -93 -128 -112
Net Income / (Loss) Continuing Operations		 -86 -187 -115 -103 -108 -111 -95 -100 -93 -128 -112
Total Pre-Tax Income 		-86 -188 -115 -102 -108 -110 -95 -100 -93 -130 -112
Total Operating Income		 -114 -198 -100 -101 -117 -126 -111 -106 -99 -121 -121
Total Gross Profit		 139 150 103 105 117 194 129 151 172 182 197
Total Revenue		 143 155 168 177 191 202 203 232 265 281 302
Operating Revenue		 143 155 168 177 191 202 203 232 265 281 302
Total Cost of Revenue		 3.97 5.10 65 72 74 8.13 75 81 94 99 105
Operating Cost of Revenue		 3.97 5.10 65 72 74 8.13 75 81 94 99 105
Total Operating Expenses		 253 347 203 205 234 320 240 257 271 303 318
Selling, General & Admin Expense		 36 121 39 40 49 52 47 50 53 61 58
Marketing Expense		 69 79 80 82 98 105 104 120 127 143 169
Research & Development Expense		 94 90 84 83 87 94 89 87 90 98 91
Total Other Income / (Expense), net		 29 11 -15 -1.88 9.60 17 16 6.55 6.40 -9.42 9.65
Interest Expense		 - - 0.65 0.65 0.65 - 0.79 0.98 0.94 1.18 1.35
Interest & Investment Income		 12 14 15 14 13 12 9.11 7.56 7.39 10 11
Other Income / (Expense), net		 17 -3.32 -29 -15 -3.01 4.67 7.85 -0.03 -0.05 -18 -0.16
Income Tax Expense		 0.49 -0.54 0.41 0.13 0.03 0.72 0.29 0.04 0.14 -1.73 0.37
Basic Earnings per Share		 ($0.73) ($1.58) ($0.94) ($0.84) ($0.88) ($0.90) ($0.77) ($0.80) ($0.74) ($1.01) ($0.85)
Weighted Average Basic Shares Outstanding		 117.74M 111.99M 121.71M 122.45M 123.05M 122.75M 123.87M 124.11M 124.81M 125.37M 131.27M
Diluted Earnings per Share		 ($0.73) ($1.58) ($0.94) ($0.84) ($0.88) ($0.90) ($0.77) ($0.80) ($0.74) ($1.01) ($0.85)
Weighted Average Diluted Shares Outstanding		 117.74M 111.99M 121.71M 122.45M 123.05M 122.75M 123.87M 124.11M 124.81M 125.37M 131.27M
Weighted Average Basic & Diluted Shares Outstanding		 117.99M 121.71M 122.37M 123.02M 123.55M 123.42M 123.89M 124.71M 126.04M 131.17M 132.60M

Annual Cash Flow Statements for Guardant Health

This table details how cash moves in and out of Guardant Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 29 39 68 2.68 690 -341 -350 992 -504 -140
Net Cash From Operating Activities		 -37 -72 -72 -47 -104 -209 -309 -325 -240 -185
Net Cash From Continuing Operating Activities		 -37 -72 -72 -47 -104 -209 -309 -325 -240 -185
Net Income / (Loss) Continuing Operations		 -46 -83 -84 -68 -246 -385 -655 -479 -436 -416
Consolidated Net Income / (Loss)		 -46 -83 -84 -68 -246 -385 -655 -479 -436 -416
Depreciation Expense		 3.69 5.21 7.14 11 16 22 36 43 42 40
Amortization Expense		 0.29 0.36 -0.41 -2.31 8.75 15 7.16 -14 -6.77 -5.88
Non-Cash Adjustments To Reconcile Net Income		 3.00 10 6.48 18 159 190 216 40 186 175
Changes in Operating Assets and Liabilities, net		 2.45 -4.99 -1.13 -6.83 -42 -52 86 85 -25 23
Net Cash From Investing Activities		 26 -170 -153 -318 -617 -63 150 840 -261 -627
Net Cash From Continuing Investing Activities		 26 -170 -153 -318 -617 -63 150 840 -261 -627
Purchase of Property, Plant & Equipment		 -1.77 -6.68 -20 -19 -36 -75 -77 -20 -35 -48
Acquisitions		 0.00 0.00 0.00 -9.83 -18 - - 0.00 0.00 -59
Purchase of Investments		 -341 -237 -287 -614 -1,126 -901 -304 -635 -307 -818
Sale and/or Maturity of Investments		 369 75 155 325 563 952 555 1,496 89 307
Other Investing Activities, net		 - -2.30 0.00 -0.07 0.00 -39 -24 - -7.50 -9.00
Net Cash From Financing Activities		 40 282 293 367 1,410 -67 -189 477 -1.00 671
Net Cash From Continuing Financing Activities		 40 282 293 367 1,410 -67 -189 477 -1.00 671
Repayment of Debt		 - -0.24 - 0.00 0.00 -0.93 -1.14 6.03 -0.15 -21
Repurchase of Common Equity		 -0.10 -7.22 -4.56 -0.72 -1.13 0.00 0.00 -21 0.00 -63
Issuance of Debt		 0.00 - 0.00 0.00 1,133 - - 0.00 0.00 403
Issuance of Common Equity		 0.19 0.00 295 357 363 9.75 9.32 503 12 359
Other Financing Activities, net		 -0.11 -25 2.71 11 -84 -76 -197 -11 -13 -6.28
Effect of Exchange Rate Changes		 - - - 0.08 0.46 -1.69 -1.60 -0.91 -1.77 0.49
Cash Interest Paid		 2.24 1.34 1.25 1.18 - - - 0.00 0.00 3.77
Cash Income Taxes Paid		 0.01 0.03 0.10 0.30 0.33 0.39 1.33 1.97 1.01 0.87

Quarterly Cash Flow Statements for Guardant Health

This table details how cash moves in and out of Guardant Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 186 676 -4.43 -94 -347 -59 174 -68 -46 -200 612
Net Cash From Operating Activities		 -78 -79 -30 -94 -51 -65 -63 -60 -35 -26 -66
Net Cash From Continuing Operating Activities		 -78 -79 -30 -94 -51 -65 -63 -60 -35 -26 -66
Net Income / (Loss) Continuing Operations		 -86 -187 -115 -103 -108 -111 -95 -100 -93 -128 -112
Consolidated Net Income / (Loss)		 -86 -187 -115 -103 -108 -111 -95 -100 -93 -128 -112
Depreciation Expense		 11 11 11 11 11 10 10 10 9.41 10 9.44
Amortization Expense		 -7.18 -2.00 - 0.64 -2.28 -3.31 -0.79 - - - -6.99
Non-Cash Adjustments To Reconcile Net Income		 5.10 26 57 42 51 32 37 41 42 56 59
Changes in Operating Assets and Liabilities, net		 -0.64 73 17 -45 -2.87 7.26 -14 -11 6.06 42 -15
Net Cash From Investing Activities		 261 663 28 -5.08 -295 11 303 -11 -14 -905 699
Net Cash From Continuing Investing Activities		 261 663 28 -5.08 -295 11 303 -11 -14 -905 699
Purchase of Property, Plant & Equipment		 -2.37 -4.08 -6.93 -5.08 -4.20 -19 -4.46 -5.65 -10 -28 -5.58
Purchase of Investments		 -69 -5.59 - - -307 - 0.00 - 5.00 -818 -250
Sale and/or Maturity of Investments		 336 668 35 - 19 34 307 - - - 955
Net Cash From Financing Activities		 3.81 91 -1.07 5.90 -2.89 -2.94 -67 1.62 4.33 732 -22
Net Cash From Continuing Financing Activities		 3.81 91 -1.07 5.90 -2.89 -2.94 -67 1.62 4.33 732 -22
Repayment of Debt		 5.95 0.12 0.26 -0.44 -0.03 0.06 -12 -0.19 2.88 -12 -4.58
Repurchase of Common Equity		 0.79 -0.65 0.00 - - - -45 - - -18 0.00
Other Financing Activities, net		 -2.93 -2.97 -1.33 -0.88 -2.85 -7.50 -9.70 -5.86 1.46 7.83 -17
Effect of Exchange Rate Changes		 -0.53 1.03 -1.14 -0.84 1.90 -1.70 0.77 0.94 -0.53 -0.69 -0.19

Annual Balance Sheets for Guardant Health

This table presents Guardant Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 343 587 963 2,272 2,204 1,610 1,786 1,486 2,014
Total Current Assets		 243 469 597 1,888 1,114 1,192 1,347 1,055 1,466
Cash & Equivalents		 72 141 143 833 492 142 1,134 526 378
Short-Term Investments		 149 278 380 962 441 870 35 314 823
Accounts Receivable		 13 36 48 53 98 97 89 110 138
Inventories, net		 7.29 9.14 15 23 31 52 62 71 86
Prepaid Expenses		 1.54 5.20 11 17 53 32 28 34 41
Plant, Property, & Equipment, net		 16 31 44 63 124 168 145 137 146
Total Noncurrent Assets		 84 87 322 321 966 250 294 294 402
Goodwill		 - 0.00 3.29 3.29 3.29 3.29 3.29 3.29 77
Intangible Assets		 8.74 7.80 8.52 16 14 12 8.98 6.76 26
Other Noncurrent Operating Assets		 1.97 2.05 41 55 250 235 282 284 299
Total Liabilities & Shareholders' Equity		 343 587 963 2,272 2,204 1,610 1,786 1,486 2,014
Total Liabilities		 34 62 115 916 1,559 1,550 1,628 1,625 2,113
Total Current Liabilities		 20 47 73 67 195 193 206 226 303
Accounts Payable		 5.00 11 16 7.34 105 176 52 39 54
Accrued Expenses		 6.41 7.18 26 23 - - 63 68 78
Current Deferred Revenue		 3.11 16 12 8.55 11 17 18 35 51
Current Employee Benefit Liabilities		 4.91 13 19 28 - - 73 83 120
Total Noncurrent Liabilities		 15 16 42 849 1,365 1,357 1,422 1,400 1,810
Long-Term Debt		 - - 0.00 806 1,135 1,137 1,140 1,143 1,504
Other Noncurrent Operating Liabilities		 7.71 7.66 42 43 230 219 282 257 306
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 309 483 798 1,298 645 60 159 -140 -99
Total Preferred & Common Equity		 309 483 798 1,298 645 60 159 -140 -99
Preferred Stock		 500 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -191 483 798 1,298 645 60 159 -140 -99
Common Stock		 4.90 764 1,150 1,902 1,658 1,742 2,304 2,444 2,900
Retained Earnings		 -196 -281 -353 -607 -1,008 -1,662 -2,142 -2,578 -2,995
Accumulated Other Comprehensive Income / (Loss)		 -0.53 -0.08 1.11 2.70 -4.76 -20 -3.68 -5.20 -4.85

Quarterly Balance Sheets for Guardant Health

This table presents Guardant Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,702 1,512 1,840 1,797 1,705 1,609 1,539 1,344 1,332 1,277 1,915
Total Current Assets		 1,131 1,104 1,398 1,347 1,309 1,290 1,227 927 883 829 1,368
Cash & Equivalents		 158 224 271 457 1,129 1,035 688 699 629 580 989
Short-Term Investments		 800 713 954 697 0.00 0.00 311 0.00 0.00 0.00 113
Accounts Receivable		 86 87 86 89 85 101 88 115 130 116 137
Inventories, net		 63 46 61 77 63 67 72 77 84 90 84
Prepaid Expenses		 24 34 26 26 32 87 67 36 40 43 43
Plant, Property, & Equipment, net		 168 163 156 148 138 132 125 129 126 125 150
Total Noncurrent Assets		 403 244 287 303 258 187 187 288 322 323 398
Goodwill		 3.29 3.29 3.29 3.29 3.29 3.29 3.29 3.29 3.29 3.29 77
Intangible Assets		 12 11 10 9.67 8.29 7.74 7.25 6.28 5.86 5.48 26
Other Noncurrent Operating Assets		 230 230 273 290 246 176 176 278 313 315 295
Total Liabilities & Shareholders' Equity		 1,702 1,512 1,840 1,797 1,705 1,609 1,539 1,344 1,332 1,277 1,915
Total Liabilities		 1,535 1,556 1,547 1,569 1,636 1,611 1,599 1,595 1,637 1,631 2,096
Total Current Liabilities		 175 204 201 227 220 202 197 226 238 237 292
Accounts Payable		 41 191 189 205 38 42 15 50 45 20 75
Accrued Expenses		 63 - - - 67 71 72 76 71 72 78
Current Deferred Revenue		 13 14 12 21 23 29 30 36 54 47 48
Current Employee Benefit Liabilities		 57 - - - 93 59 81 64 68 98 91
Total Noncurrent Liabilities		 1,360 1,352 1,346 1,342 1,416 1,409 1,401 1,369 1,399 1,394 1,804
Long-Term Debt		 1,137 1,138 1,139 1,139 1,141 1,141 1,142 1,116 1,116 1,115 1,503
Other Noncurrent Operating Liabilities		 223 214 208 203 276 268 260 253 284 280 301
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 167 -45 293 228 68 -1.61 -60 -251 -305 -354 -181
Total Preferred & Common Equity		 167 -45 293 228 68 -1.61 -60 -251 -305 -354 -181
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 167 -45 293 228 68 -1.61 -60 -251 -305 -354 -181
Common Stock		 1,716 1,764 2,170 2,189 2,330 2,364 2,410 2,472 2,517 2,561 2,931
Retained Earnings		 -1,522 -1,796 -1,869 -1,955 -2,257 -2,359 -2,467 -2,673 -2,773 -2,866 -3,107
Accumulated Other Comprehensive Income / (Loss)		 -27 -12 -8.47 -5.68 -4.80 -5.64 -3.28 -4.66 -3.72 -4.26 -5.15

Annual Metrics And Ratios for Guardant Health

This table displays calculated financial ratios and metrics derived from Guardant Health's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 97.40% 81.85% 136.52% 33.75% 30.32% 20.31% 25.45% 31.04% 32.88%
EBITDA Growth		 0.00% -80.86% -13.05% 10.22% -209.50% -53.70% -47.65% 6.69% 6.60% 8.15%
EBIT Growth		 0.00% -77.14% -13.61% 6.75% -205.42% -53.53% -44.41% 8.19% 4.96% 7.91%
NOPAT Growth		 0.00% -74.73% -21.32% 11.37% -209.51% -61.21% -32.45% -3.74% 21.45% 1.43%
Net Income Growth		 0.00% -80.37% -1.25% 19.48% -262.98% -56.23% -70.12% 26.76% 8.98% 4.61%
EPS Growth		 0.00% -100.28% 60.40% 70.00% -209.52% -53.85% -60.25% 33.23% 16.82% 6.74%
Operating Cash Flow Growth		 0.00% -96.77% 0.07% 34.70% -120.49% -101.12% -48.06% -5.01% 26.19% 22.97%
Free Cash Flow Firm Growth		 0.00% 0.00% -15.34% -8.68% -183.12% -30.47% -32.25% 18.97% -1.31% -0.82%
Invested Capital Growth		 0.00% 0.00% 93.51% 98.42% 113.46% 23.78% 25.02% -30.23% 25.31% 24.66%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 16.29% 5.68% 8.66% 4.36% 5.26% 6.75% 8.80%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 3.30% -32.21% 4.38% -14.87% -15.16% 14.80% -6.17%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 1.35% -34.02% 4.37% -14.02% -13.28% 14.06% -4.13%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 1.70% -34.36% -1.74% -9.65% -10.01% 13.89% 1.17%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 4.45% -40.45% 5.11% -11.52% -10.90% 14.84% -4.39%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -156.76% -36.13% 1.72% -8.09% -5.16% 16.04% -3.43%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -13.43% -8.78% -38.48% -9.29% -4.65% 3.57% 5.59% 17.11%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -34.55% 13.52% -13.24% 11.59% -48.97% 14.94%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 54.88% 43.68% -10.65% -1.26% -38.90% 96.92% 12.76%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 99.77% 94.51% 96.29% 96.05% 93.80% 96.65% 98.19% 96.18% 96.05% 64.46%
EBITDA Margin		 -157.90% -144.67% -89.93% -34.14% -78.99% -93.17% -114.35% -85.05% -60.62% -42.15%
Operating Margin		 -173.66% -153.71% -102.54% -38.42% -88.92% -110.00% -121.10% -100.14% -60.03% -44.53%
EBIT Margin		 -173.66% -155.83% -97.35% -38.38% -87.65% -103.26% -123.94% -90.71% -65.79% -45.59%
Profit (Net Income) Margin		 -182.74% -166.97% -92.97% -31.65% -85.89% -102.98% -145.61% -85.02% -59.05% -42.39%
Tax Burden Percent		 100.01% 100.01% 100.05% 97.32% 100.15% 100.08% 100.17% 100.14% 100.30% 99.70%
Interest Burden Percent		 105.21% 107.14% 95.45% 84.74% 97.85% 99.65% 117.28% 93.59% 89.49% 93.26%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -730.09% -301.77% -135.93% -201.86% -213.54% -227.24% -249.91% -212.00% -167.25%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -709.95% -296.91% -134.35% -195.17% -202.33% -79.31% -422.53% -303.90% -203.68%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 676.15% 281.55% 126.05% 179.51% 175.08% 41.59% -188.21% -4,372.47% 515.66%
Return on Equity (ROE)		 0.00% -53.93% -20.22% -9.88% -22.35% -38.47% -185.65% -438.13% -4,584.47% 348.42%
Cash Return on Invested Capital (CROIC)		 0.00% -930.09% -365.48% -201.89% -274.26% -234.80% -249.48% -214.31% -234.47% -189.20%
Operating Return on Assets (OROA)		 0.00% -22.65% -18.97% -10.62% -15.54% -17.24% -29.21% -30.12% -29.72% -25.59%
Return on Assets (ROA)		 0.00% -24.27% -18.11% -8.76% -15.23% -17.19% -34.32% -28.23% -26.67% -23.79%
Return on Common Equity (ROCE)		 0.00% 33.44% -7.08% -9.23% -21.27% -37.37% -185.65% -438.13% -4,584.47% 348.42%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -26.97% -17.44% -8.50% -18.97% -59.65% -1,087.72% -302.14% 312.48% 0.00%
Net Operating Profit after Tax (NOPAT)		 -31 -54 -65 -58 -178 -288 -381 -395 -311 -306
NOPAT Margin		 -121.56% -107.60% -71.78% -26.90% -62.24% -77.00% -84.77% -70.10% -42.02% -31.17%
Net Nonoperating Expense Percent (NNEP)		 0.00% -20.14% -4.86% -1.58% -6.69% -11.21% -147.93% 172.61% 91.90% 36.43%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -31.82% -30.44% -30.96% -21.79%
Cost of Revenue to Revenue		 0.23% 5.49% 3.71% 3.95% 6.20% 3.35% 1.81% 3.82% 3.95% 35.54%
SG&A Expenses to Revenue		 39.29% 73.79% 39.93% 28.64% 67.23% 55.30% 36.47% 42.42% 24.37% 21.53%
R&D to Revenue		 43.01% 51.29% 55.95% 40.25% 52.27% 70.45% 83.15% 65.11% 47.06% 37.09%
Operating Expenses to Revenue		 273.42% 248.22% 198.83% 134.48% 182.72% 206.65% 219.29% 196.32% 156.07% 108.99%
Earnings before Interest and Taxes (EBIT)		 -44 -78 -88 -82 -251 -386 -557 -512 -486 -448
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -72 -82 -73 -226 -348 -514 -480 -448 -414
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 6.67 9.19 9.92 15.76 46.30 20.11 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 6.78 9.33 10.07 16.20 61.69 21.80 0.00 0.00
Price to Revenue (P/Rev)		 9.41 4.77 35.56 34.23 44.94 27.21 6.20 5.66 5.11 13.11
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 30.19 97.40 116.93 97.22 64.89 15.63 24.33 25.03 64.88
Enterprise Value to Revenue (EV/Rev)		 0.00 8.90 30.55 30.77 40.83 25.88 6.48 5.61 5.52 13.42
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.59 1.76 18.90 7.18 -8.18 -15.15
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.59 1.76 18.90 7.18 -8.18 -15.15
Financial Leverage		 0.00 -0.95 -0.95 -0.94 -0.92 -0.87 -0.52 0.45 14.39 -2.53
Leverage Ratio		 0.00 1.11 1.12 1.13 1.47 2.24 5.41 15.52 171.88 -14.64
Compound Leverage Factor		 0.00 1.19 1.07 0.96 1.44 2.23 6.34 14.52 153.81 -13.66
Debt to Total Capital		 0.00% 0.21% 0.00% 0.00% 37.30% 63.76% 94.97% 87.78% 113.92% 107.07%
Short-Term Debt to Total Capital		 0.00% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.15% 0.00% 0.00% 37.30% 63.76% 94.97% 87.78% 113.92% 107.07%
Preferred Equity to Total Capital		 0.00% 161.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 7.96% 5.85% 2.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -61.88% 92.04% 94.15% 60.06% 36.24% 5.03% 12.22% -13.92% -7.07%
Debt to EBITDA		 0.00 -0.01 0.00 0.00 -3.56 -3.26 -2.21 -2.38 -2.55 -3.63
Net Debt to EBITDA		 0.00 4.08 0.00 0.00 5.45 1.42 -0.25 0.06 -0.68 -0.73
Long-Term Debt to EBITDA		 0.00 -0.01 0.00 0.00 -3.56 -3.26 -2.21 -2.38 -2.55 -3.63
Debt to NOPAT		 0.00 -0.01 0.00 0.00 -4.52 -3.94 -2.98 -2.88 -3.68 -4.91
Net Debt to NOPAT		 0.00 5.48 0.00 0.00 6.92 1.72 -0.33 0.07 -0.97 -0.99
Long-Term Debt to NOPAT		 0.00 -0.01 0.00 0.00 -4.52 -3.94 -2.98 -2.88 -3.68 -4.91
Altman Z-Score		 0.00 3.53 30.82 38.52 8.79 3.36 -0.49 -0.36 -0.95 2.02
Noncontrolling Interest Sharing Ratio		 0.00% 162.01% 65.00% 6.66% 4.84% 2.85% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 12.38 9.99 8.21 28.27 5.72 6.17 6.54 4.68 4.84
Quick Ratio		 0.00 11.93 9.69 7.85 27.66 5.29 5.74 6.11 4.21 4.42
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -68 -79 -86 -242 -316 -418 -339 -343 -346
Operating Cash Flow to CapEx		 -2,078.71% -1,081.20% -357.30% -251.82% -287.31% -278.56% -399.51% -1,586.33% -683.65% -382.48%
Free Cash Flow to Firm to Interest Expense		 0.00 -8.78 -62.99 -72.51 -50.87 -122.75 -4.19 0.00 0.00 -88.85
Operating Cash Flow to Interest Expense		 -12.16 -9.29 -57.70 -39.91 -21.81 -81.11 -3.10 0.00 0.00 -47.41
Operating Cash Flow Less CapEx to Interest Expense		 -12.75 -10.15 -73.85 -55.76 -29.40 -110.23 -3.88 0.00 0.00 -59.81
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.15 0.19 0.28 0.18 0.17 0.24 0.33 0.45 0.56
Accounts Receivable Turnover		 0.00 3.90 3.74 5.12 5.66 4.95 4.61 6.06 7.43 7.92
Inventory Turnover		 0.00 0.38 0.41 0.70 0.94 0.47 0.20 0.38 0.44 4.45
Fixed Asset Turnover		 0.00 3.11 3.85 5.74 5.39 3.99 3.08 3.60 5.24 6.95
Accounts Payable Turnover		 0.00 0.55 0.43 0.63 1.51 0.22 0.06 0.19 0.65 7.51
Days Sales Outstanding (DSO)		 0.00 93.64 97.61 71.23 64.47 73.73 79.13 60.20 49.15 46.11
Days Inventory Outstanding (DIO)		 0.00 972.49 890.96 524.26 389.29 778.50 1,847.73 962.75 830.93 82.08
Days Payable Outstanding (DPO)		 0.00 667.01 848.48 578.63 241.78 1,643.33 6,314.91 1,929.44 563.98 48.63
Cash Conversion Cycle (CCC)		 0.00 399.12 140.09 16.86 211.98 -791.11 -4,388.06 -906.49 316.11 79.56
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 15 28 56 120 149 186 130 163 203
Invested Capital Turnover		 0.00 6.79 4.20 5.05 3.24 2.77 2.68 3.57 5.05 5.37
Increase / (Decrease) in Invested Capital		 0.00 15 14 28 64 29 37 -56 33 40
Enterprise Value (EV)		 0.00 444 2,769 6,596 11,706 9,672 2,912 3,163 4,077 13,176
Market Capitalization		 238 238 3,223 7,338 12,884 10,168 2,786 3,192 3,775 12,874
Book Value per Share		 $0.00 ($15.21) $5.63 $8.50 $12.99 $6.35 $0.59 $1.34 ($1.13) ($0.79)
Tangible Book Value per Share		 $0.00 ($15.90) $5.54 $8.38 $12.79 $6.17 $0.44 $1.24 ($1.21) ($1.61)
Total Capital		 0.00 309 525 848 2,162 1,780 1,198 1,299 1,003 1,405
Total Debt		 0.00 0.66 0.00 0.00 806 1,135 1,137 1,140 1,143 1,504
Total Long-Term Debt		 0.00 0.46 0.00 0.00 806 1,135 1,137 1,140 1,143 1,504
Net Debt		 0.00 -294 -497 -792 -1,235 -496 126 -29 303 302
Capital Expenditures (CapEx)		 1.77 6.68 20 19 36 75 77 20 35 48
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 2.19 3.09 1.82 27 -13 -13 -27 -10 -38
Debt-free Net Working Capital (DFNWC)		 0.00 224 422 525 1,822 919 998 1,141 830 1,163
Net Working Capital (NWC)		 0.00 223 422 525 1,822 919 998 1,141 830 1,163
Net Nonoperating Expense (NNE)		 15 30 19 10 68 97 274 84 126 110
Net Nonoperating Obligations (NNO)		 0.00 -294 -497 -792 -1,235 -496 126 -29 303 302
Total Depreciation and Amortization (D&A)		 3.98 5.57 6.72 9.10 25 38 43 32 38 34
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 4.39% 3.40% 0.85% 9.30% -3.56% -2.86% -4.87% -1.41% -3.90%
Debt-free Net Working Capital to Revenue		 0.00% 448.43% 465.64% 244.72% 635.28% 246.07% 222.09% 202.36% 112.25% 118.46%
Net Working Capital to Revenue		 0.00% 448.03% 465.64% 244.72% 635.28% 246.07% 222.09% 202.36% 112.25% 118.46%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.53) ($7.07) ($2.80) ($0.84) ($2.60) ($4.00) ($6.41) ($4.28) ($3.56) ($3.32)
Adjusted Weighted Average Basic Shares Outstanding		 13.05M 12.58M 85.93M 94.38M 100.43M 101.31M 102.18M 111.99M 122.75M 125.37M
Adjusted Diluted Earnings per Share		 ($3.53) ($7.07) ($2.80) ($0.84) ($2.60) ($4.00) ($6.41) ($4.28) ($3.56) ($3.32)
Adjusted Weighted Average Diluted Shares Outstanding		 13.05M 12.58M 85.93M 94.38M 100.43M 101.31M 102.18M 111.99M 122.75M 125.37M
Adjusted Basic & Diluted Earnings per Share		 ($3.53) ($7.07) ($2.80) ($0.84) ($2.60) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.05M 12.58M 30.40M 90.60M 97.50M 101.87M 102.66M 121.71M 123.42M 131.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -54 -65 -58 -178 -288 -381 -395 -311 -306
Normalized NOPAT Margin		 -121.56% -107.60% -71.78% -26.90% -62.24% -77.00% -84.77% -70.10% -42.02% -31.17%
Pre Tax Income Margin		 -182.71% -166.96% -92.92% -32.52% -85.76% -102.89% -145.36% -84.90% -58.87% -42.52%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -14.53 -9.99 -70.54 -69.67 -52.73 -149.72 -5.58 0.00 0.00 -114.89
NOPAT to Interest Expense		 -10.17 -6.90 -52.01 -48.82 -37.45 -111.64 -3.82 0.00 0.00 -78.54
EBIT Less CapEx to Interest Expense		 -15.11 -10.85 -86.69 -85.52 -60.32 -178.84 -6.36 0.00 0.00 -127.29
NOPAT Less CapEx to Interest Expense		 -10.76 -7.75 -68.16 -64.67 -45.04 -140.76 -4.60 0.00 0.00 -90.94
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.22% -8.68% -5.41% -1.07% -0.46% 0.00% 0.00% -4.41% 0.00% -15.06%

Quarterly Metrics And Ratios for Guardant Health

This table displays calculated financial ratios and metrics derived from Guardant Health's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 131,170,441.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 131,170,441.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.85
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 21.83% 22.19% 30.90% 29.23% 33.87% 30.16% 20.76% 30.95% 38.50% 39.37% 48.26%
EBITDA Growth		 39.33% -49.04% 6.68% -51.10% -20.70% 40.53% 21.29% 8.32% 18.32% -16.40% -26.99%
EBIT Growth		 40.70% -42.59% 5.09% -47.74% -24.50% 39.60% 19.89% 8.06% 17.70% -14.65% -17.75%
NOPAT Growth		 21.48% -35.17% 25.64% 15.88% -3.33% 36.22% -11.39% -5.76% 15.63% 4.10% -9.28%
Net Income Growth		 46.85% -33.67% 13.89% -41.03% -25.15% 40.65% 17.24% 2.66% 13.95% -15.75% -17.78%
EPS Growth		 53.80% -15.33% 27.69% -25.37% -20.55% 43.04% 18.09% 4.76% 15.91% -12.22% -10.39%
Operating Cash Flow Growth		 0.47% 13.25% 59.32% 0.01% 34.36% 18.06% -107.00% 35.87% 30.64% 59.12% -4.68%
Free Cash Flow Firm Growth		 15.89% 41.30% 112.92% 144.45% 146.28% -47.78% -2,442.75% -576.04% -447.69% -3.02% 16.64%
Invested Capital Growth		 12.76% -30.23% -49.10% -49.45% -61.12% 25.31% 109.67% 73.28% 117.69% 24.66% 31.54%
Revenue Q/Q Growth		 4.29% 8.41% 8.67% 5.19% 8.04% 5.40% 0.82% 14.06% 14.27% 6.06% 7.25%
EBITDA Q/Q Growth		 -34.19% -106.84% 38.87% 10.94% -7.19% -1.91% 18.57% -3.70% 7.02% -43.95% 7.73%
EBIT Q/Q Growth		 -23.36% -107.77% 35.86% 10.12% -3.95% -0.80% 14.93% -3.15% 6.95% -40.43% 12.63%
NOPAT Q/Q Growth		 5.08% -73.95% 49.53% -0.94% -16.61% -7.36% 11.85% 4.17% 6.98% -22.04% -0.45%
Net Income Q/Q Growth		 -18.32% -117.23% 38.52% 10.75% -4.99% -3.02% 14.28% -4.98% 7.18% -38.58% 12.78%
EPS Q/Q Growth		 -8.96% -116.44% 40.51% 10.64% -4.76% -2.27% 14.44% -3.90% 7.50% -36.49% 15.84%
Operating Cash Flow Q/Q Growth		 17.26% -1.20% 61.53% -210.40% 45.68% -26.35% 2.83% 3.83% 41.26% 25.53% -148.83%
Free Cash Flow Firm Q/Q Growth		 -45.13% 20.89% 108.60% 350.17% 51.12% -352.60% -36.33% 8.53% -10.38% 25.16% -10.32%
Invested Capital Q/Q Growth		 3.02% -38.90% -38.75% 31.10% -20.75% 96.92% 2.49% 8.34% -0.44% 12.76% 8.15%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 97.23% 96.71% 96.44% 96.22% 95.62% 95.97% 63.28% 65.01% 64.71% 64.63% 65.22%
EBITDA Margin		 -64.89% -123.80% -69.64% -58.96% -58.50% -56.57% -45.68% -41.53% -33.80% -45.87% -39.46%
Operating Margin		 -79.38% -127.38% -59.16% -56.77% -61.28% -62.42% -54.57% -45.85% -37.33% -42.95% -40.23%
EBIT Margin		 -67.58% -129.52% -76.45% -65.32% -62.85% -60.10% -50.71% -45.86% -37.34% -49.45% -40.28%
Profit (Net Income) Margin		 -60.20% -120.63% -68.24% -57.91% -56.28% -55.00% -46.77% -43.04% -34.96% -45.68% -37.15%
Tax Burden Percent		 100.57% 99.71% 100.35% 100.13% 100.03% 100.65% 100.31% 100.04% 100.15% 98.67% 100.33%
Interest Burden Percent		 88.57% 93.41% 88.96% 88.54% 89.52% 90.92% 91.94% 93.82% 93.49% 93.64% 91.93%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -148.30% -317.91% -211.79% -164.55% -200.94% -220.45% -239.79% -186.48% -179.44% -161.33% -157.35%
ROIC Less NNEP Spread (ROIC-NNEP)		 -352.97% -417.99% -254.37% -489.01% -241.19% -237.12% -247.91% -195.06% -186.36% -175.85% -163.98%
Return on Net Nonoperating Assets (RNNOA)		 -5.78% -186.19% -2,276.04% -33.34% -182.59% -3,411.61% 582.91% 376.28% 304.52% 445.22% 310.78%
Return on Equity (ROE)		 -154.08% -504.10% -2,487.83% -197.89% -383.53% -3,632.06% 343.12% 189.80% 125.08% 283.89% 153.43%
Cash Return on Invested Capital (CROIC)		 -190.99% -214.31% -249.40% -164.52% -156.01% -234.47% -329.10% -279.71% -309.73% -189.20% -189.31%
Operating Return on Assets (OROA)		 -20.70% -43.01% -28.70% -24.38% -26.08% -27.15% -25.75% -25.85% -23.94% -27.75% -26.70%
Return on Assets (ROA)		 -18.44% -40.06% -25.62% -21.62% -23.36% -24.85% -23.75% -24.26% -22.42% -25.64% -24.62%
Return on Common Equity (ROCE)		 -154.08% -504.10% -2,487.83% -197.89% -383.53% -3,632.06% 343.12% 189.80% 125.08% 283.89% 153.43%
Return on Equity Simple (ROE_SIMPLE)		 -189.37% 0.00% -674.97% 0.00% 852.65% 0.00% 166.09% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -79 -138 -70 -70 -82 -88 -78 -74 -69 -85 -85
NOPAT Margin		 -55.57% -89.17% -41.41% -39.74% -42.89% -43.69% -38.20% -32.10% -26.13% -30.07% -28.16%
Net Nonoperating Expense Percent (NNEP)		 204.66% 100.08% 42.57% 324.45% 40.25% 16.67% 8.12% 8.58% 6.92% 14.52% 6.63%
Return On Investment Capital (ROIC_SIMPLE)		 - -10.65% - - - -8.79% -8.98% -9.20% -9.12% -6.02% -6.42%
Cost of Revenue to Revenue		 2.77% 3.29% 3.56% 3.78% 4.38% 4.03% 36.72% 34.99% 35.29% 35.37% 34.78%
SG&A Expenses to Revenue		 25.29% 78.08% 22.94% 22.83% 25.66% 25.71% 23.08% 21.66% 20.09% 21.66% 19.20%
R&D to Revenue		 65.62% 57.95% 49.74% 46.89% 45.60% 46.35% 43.51% 37.68% 33.92% 34.94% 30.18%
Operating Expenses to Revenue		 176.61% 224.09% 155.61% 152.99% 156.89% 158.39% 117.85% 110.86% 102.04% 107.58% 105.45%
Earnings before Interest and Taxes (EBIT)		 -97 -201 -129 -116 -120 -121 -103 -106 -99 -139 -122
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -93 -192 -117 -104 -112 -114 -93 -96 -90 -129 -119
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 15.28 20.11 35.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 16.20 21.80 42.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 6.51 5.66 4.03 5.49 4.08 5.11 6.79 7.78 8.63 13.11 11.22
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 16.32 24.33 30.71 34.86 35.84 25.03 33.99 38.33 46.23 64.88 56.99
Enterprise Value to Revenue (EV/Rev)		 6.48 5.61 4.05 5.65 4.28 5.52 7.33 8.37 9.23 13.42 11.59
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 4.99 7.18 16.70 -707.54 -19.00 -8.18 -4.45 -3.65 -3.14 -15.15 -8.30
Long-Term Debt to Equity		 4.99 7.18 16.70 -707.54 -19.00 -8.18 -4.45 -3.65 -3.14 -15.15 -8.30
Financial Leverage		 0.02 0.45 8.95 0.07 0.76 14.39 -2.35 -1.93 -1.63 -2.53 -1.90
Leverage Ratio		 8.86 15.52 135.51 11.85 19.83 171.88 -16.71 -9.58 -6.79 -14.64 -7.55
Compound Leverage Factor		 7.85 14.50 120.55 10.49 17.75 156.28 -15.36 -8.99 -6.35 -13.71 -6.94
Debt to Total Capital		 83.31% 87.78% 94.35% 100.14% 105.56% 113.92% 128.97% 137.71% 146.63% 107.07% 113.69%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 83.31% 87.78% 94.35% 100.14% 105.56% 113.92% 128.97% 137.71% 146.63% 107.07% 113.69%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 16.69% 12.22% 5.65% -0.14% -5.56% -13.92% -28.97% -37.71% -46.63% -7.07% -13.69%
Debt to EBITDA		 -2.74 -2.38 -2.42 -2.25 -2.17 -2.55 -2.67 -2.72 -2.86 -3.63 -3.42
Net Debt to EBITDA		 0.04 0.06 -0.02 -0.21 -0.27 -0.68 -1.00 -1.19 -1.37 -0.73 -0.91
Long-Term Debt to EBITDA		 -2.74 -2.38 -2.42 -2.25 -2.17 -2.55 -2.67 -2.72 -2.86 -3.63 -3.42
Debt to NOPAT		 -3.17 -2.88 -3.07 -3.19 -3.17 -3.68 -3.51 -3.46 -3.60 -4.91 -4.80
Net Debt to NOPAT		 0.04 0.07 -0.03 -0.30 -0.40 -0.97 -1.31 -1.51 -1.73 -0.99 -1.28
Long-Term Debt to NOPAT		 -3.17 -2.88 -3.07 -3.19 -3.17 -3.68 -3.51 -3.46 -3.60 -4.91 -4.80
Altman Z-Score		 0.68 0.21 -0.09 0.24 -0.19 -0.14 0.14 0.39 0.73 2.53 2.23
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.94 6.54 5.95 6.40 6.22 4.68 4.11 3.71 3.50 4.84 4.68
Quick Ratio		 5.48 6.11 5.52 5.63 5.51 4.21 3.61 3.19 2.94 4.42 4.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -104 -82 7.05 32 48 -121 -165 -151 -167 -125 -138
Operating Cash Flow to CapEx		 -3,279.55% -1,931.03% -436.75% -1,851.53% -1,215.98% -341.79% -1,405.90% -1,067.18% -342.15% -94.70% -1,176.04%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 10.92 0.00 0.00 0.00 -208.68 -153.60 -176.74 -105.71 -102.16
Operating Cash Flow to Interest Expense		 0.00 0.00 -46.95 0.00 0.00 0.00 -79.25 -61.33 -37.55 -22.35 -48.72
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -57.70 0.00 0.00 0.00 -84.89 -67.07 -48.53 -45.95 -52.86
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.31 0.33 0.38 0.37 0.42 0.45 0.51 0.56 0.64 0.56 0.66
Accounts Receivable Turnover		 6.12 6.06 7.03 6.89 7.81 7.43 7.74 7.18 8.85 7.92 8.55
Inventory Turnover		 0.28 0.38 0.36 0.34 0.35 0.44 0.55 0.63 0.82 4.45 4.71
Fixed Asset Turnover		 3.39 3.60 4.00 4.47 5.07 5.24 5.78 6.41 7.23 6.95 7.73
Accounts Payable Turnover		 0.16 0.19 0.17 0.19 0.24 0.65 0.88 1.09 3.74 7.51 6.08
Days Sales Outstanding (DSO)		 59.61 60.20 51.92 53.01 46.73 49.15 47.16 50.81 41.26 46.11 42.72
Days Inventory Outstanding (DIO)		 1,288.63 962.75 1,022.02 1,069.35 1,040.61 830.93 662.31 581.20 446.57 82.08 77.54
Days Payable Outstanding (DPO)		 2,264.60 1,929.44 2,129.99 1,938.41 1,538.18 563.98 412.62 335.72 97.70 48.63 60.06
Cash Conversion Cycle (CCC)		 -916.36 -906.49 -1,056.05 -816.05 -450.84 316.11 296.85 296.29 390.12 79.56 60.19
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 213 130 80 104 83 163 167 181 180 203 220
Invested Capital Turnover		 2.67 3.57 5.11 4.14 4.68 5.05 6.28 5.81 6.87 5.37 5.59
Increase / (Decrease) in Invested Capital		 24 -56 -77 -102 -130 33 87 77 97 40 53
Enterprise Value (EV)		 3,473 3,163 2,446 3,640 2,965 4,077 5,676 6,934 8,326 13,176 12,517
Market Capitalization		 3,488 3,192 2,434 3,534 2,822 3,775 5,258 6,447 7,792 12,874 12,116
Book Value per Share		 $1.94 $1.34 $0.56 ($0.01) ($0.49) ($1.13) ($2.03) ($2.47) ($2.84) ($0.79) ($1.38)
Tangible Book Value per Share		 $1.83 $1.24 $0.47 ($0.10) ($0.57) ($1.21) ($2.11) ($2.54) ($2.91) ($1.61) ($2.16)
Total Capital		 1,368 1,299 1,209 1,140 1,082 1,003 866 810 760 1,405 1,322
Total Debt		 1,139 1,140 1,141 1,141 1,142 1,143 1,116 1,116 1,115 1,504 1,503
Total Long-Term Debt		 1,139 1,140 1,141 1,141 1,142 1,143 1,116 1,116 1,115 1,504 1,503
Net Debt		 -15 -29 11 106 143 303 418 486 535 302 401
Capital Expenditures (CapEx)		 2.37 4.08 6.93 5.08 4.20 19 4.46 5.65 10 28 5.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -35 -27 -41 53 30 -10 2.70 16 12 -38 -27
Debt-free Net Working Capital (DFNWC)		 1,120 1,141 1,089 1,088 1,029 830 701 645 592 1,163 1,075
Net Working Capital (NWC)		 1,120 1,141 1,089 1,088 1,029 830 701 645 592 1,163 1,075
Net Nonoperating Expense (NNE)		 6.62 49 45 32 26 23 17 25 23 44 27
Net Nonoperating Obligations (NNO)		 -15 -29 11 106 143 303 418 486 535 302 401
Total Depreciation and Amortization (D&A)		 3.85 8.87 11 11 8.32 7.14 10 10 9.41 10 2.46
Debt-free, Cash-free Net Working Capital to Revenue		 -6.47% -4.87% -6.74% 8.26% 4.38% -1.41% 0.35% 1.91% 1.32% -3.90% -2.54%
Debt-free Net Working Capital to Revenue		 209.07% 202.36% 180.30% 169.06% 148.70% 112.25% 90.60% 77.82% 65.59% 118.46% 99.55%
Net Working Capital to Revenue		 209.07% 202.36% 180.30% 169.06% 148.70% 112.25% 90.60% 77.82% 65.59% 118.46% 99.55%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.73) ($1.58) ($0.94) ($0.84) ($0.88) ($0.90) ($0.77) ($0.80) ($0.74) ($1.01) ($0.85)
Adjusted Weighted Average Basic Shares Outstanding		 117.74M 111.99M 121.71M 122.45M 123.05M 122.75M 123.87M 124.11M 124.81M 125.37M 131.27M
Adjusted Diluted Earnings per Share		 ($0.73) ($1.58) ($0.94) ($0.84) ($0.88) ($0.90) ($0.77) ($0.80) ($0.74) ($1.01) ($0.85)
Adjusted Weighted Average Diluted Shares Outstanding		 117.74M 111.99M 121.71M 122.45M 123.05M 122.75M 123.87M 124.11M 124.81M 125.37M 131.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 117.99M 121.71M 122.37M 123.02M 123.55M 123.42M 123.89M 124.71M 126.04M 131.17M 132.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -79 -138 -70 -70 -82 -88 -78 -74 -69 -85 -85
Normalized NOPAT Margin		 -55.57% -89.17% -41.41% -39.74% -42.89% -43.69% -38.20% -32.10% -26.13% -30.07% -28.16%
Pre Tax Income Margin		 -59.86% -120.98% -68.00% -57.83% -56.26% -54.65% -46.63% -43.03% -34.91% -46.30% -37.03%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -199.69 0.00 0.00 0.00 -130.46 -108.28 -105.02 -117.86 -90.21
NOPAT to Interest Expense		 0.00 0.00 -108.18 0.00 0.00 0.00 -98.27 -75.78 -73.48 -71.66 -63.06
EBIT Less CapEx to Interest Expense		 0.00 0.00 -210.45 0.00 0.00 0.00 -136.09 -114.03 -116.00 -141.46 -94.35
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -118.93 0.00 0.00 0.00 -103.90 -81.52 -84.46 -95.26 -67.20
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -4.74% -4.41% 0.00% 0.03% -0.13% 0.00% -10.81% -10.88% -11.29% -15.06% -4.08%

Financials Breakdown Chart

Key Financial Trends

Guardant Health showed meaningful revenue growth in Q1 2026, but the company remains deeply unprofitable and continues to burn cash from operations. The latest quarter suggests improving top-line momentum and a very strong liquidity position, yet operating losses are still large and the balance sheet carries substantial debt.

  • Revenue growth remained solid. Q1 2026 revenue rose to $301.7 million from $281.3 million in Q4 2025 and $203.5 million in Q1 2025, showing the business is still expanding.
  • Gross profit improved in absolute dollars. Q1 2026 gross profit was $196.7 million, up from $181.8 million in Q4 2025 and well above prior-year levels.
  • Cash and investments increased sharply. Guardant ended Q1 2026 with $989.3 million in cash and equivalents plus $113.5 million in short-term investments, giving it significant near-term liquidity.
  • Investing activity boosted cash in the quarter. Net investing cash flow was strongly positive at $699.4 million, driven by $954.9 million of investment sales/maturities.
  • Operating expenses were still elevated, but marketing moderated sequentially. Marketing expense fell to $169.1 million in Q1 2026 from $143.4 million in Q4 2025? Actually, Q1 2026 was higher than Q4 2025, but expense trends remain important as the company tries to scale toward profitability.
  • R&D and SG&A remain large. Q1 2026 R&D was $91.0 million and SG&A was $57.9 million, indicating continued heavy investment in the platform.
  • Operating cash burn improved versus some prior quarters, but was still negative. Operating cash flow was -$65.6 million in Q1 2026 versus -$26.4 million in Q4 2025, so the quarter still consumed cash from operations.
  • The company remains loss-making. Q1 2026 net loss was $112.1 million, and operating loss was $121.4 million.
  • Profitability has not yet turned the corner. Over the last four years shown here, Guardant has consistently reported sizable quarterly losses, with no clear path to GAAP breakeven yet.
  • Debt is a meaningful balance-sheet burden. Long-term debt was $1.50 billion at Q1 2026, which is large relative to the company’s common equity, which remained negative at -$181.1 million.

From a trend perspective, Guardant Health looks like a company with improving revenue scale and ample liquidity, but also one that still faces persistent operating losses, heavy spending, and substantial leverage. The most encouraging development is the strong cash position, which reduces near-term funding risk. The key question for investors is whether revenue growth can continue fast enough to absorb the company’s still-large expense base and eventually lead to sustainable margins.

06/04/26 12:20 AM ETAI Generated. May Contain Errors.

Guardant Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Guardant Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Guardant Health's net income appears to be on an upward trend, with a most recent value of -$416.28 million in 2025, rising from -$46.14 million in 2016. The previous period was -$436.37 million in 2024. Find out what analysts predict for Guardant Health in the coming months.

Guardant Health's total operating income in 2025 was -$437.25 million, based on the following breakdown:
  • Total Gross Profit: $633.01 million
  • Total Operating Expenses: $1.07 billion

Over the last 9 years, Guardant Health's total revenue changed from $25.25 million in 2016 to $982.02 million in 2025, a change of 3,789.3%.

Guardant Health's total liabilities were at $2.11 billion at the end of 2025, a 30.0% increase from 2024, and a 6,054.5% increase since 2017.

In the past 8 years, Guardant Health's cash and equivalents has ranged from $72.28 million in 2017 to $1.13 billion in 2023, and is currently $378.20 million as of their latest financial filing in 2025.

Over the last 9 years, Guardant Health's book value per share changed from 0.00 in 2016 to -0.79 in 2025, a change of -78.8%.


Related Companies

Financial statements for NASDAQ:GH last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel